BioInvent International AB
STO:BINV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioInvent International AB
Selling, General & Administrative
BioInvent International AB
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioInvent International AB
STO:BINV
|
Selling, General & Administrative
-kr72.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-9%
|
|
|
Biogaia AB
STO:BIOG B
|
Selling, General & Administrative
-kr556.5m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Selling, General & Administrative
-kr741.3m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Selling, General & Administrative
-kr1.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-18%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Selling, General & Administrative
-kr7.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-22%
|
|
|
BioArctic AB
STO:BIOA B
|
Selling, General & Administrative
-kr194.8m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
BioInvent International AB
Glance View
BioInvent International AB engages in the research and development of novel and immuno-modulatory antibodies for the treatment of cancer. The company is headquartered in Lund, Skane and currently employs 84 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
See Also
What is BioInvent International AB's Selling, General & Administrative?
Selling, General & Administrative
-72.3m
SEK
Based on the financial report for Dec 31, 2025, BioInvent International AB's Selling, General & Administrative amounts to -72.3m SEK.
What is BioInvent International AB's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-9%
Over the last year, the Selling, General & Administrative growth was -27%. The average annual Selling, General & Administrative growth rates for BioInvent International AB have been -13% over the past three years , -18% over the past five years , and -9% over the past ten years .
